Coya Therapeutics has published a significant longitudinal biomarker study in the Annals of Clinical and Translational Neurology, spearheaded by Dr. David Beers and Dr. Stanley Appel. This research analyzed serum samples from 100 patients with sporadic or familial amyotrophic lateral sclerosis (ALS) against 100 age- and sex-matched healthy controls, focusing on three key biomarkers: 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL), all measured via ELISA. The findings revealed that levels of 4-HNE and LBP were significantly elevated at diagnosis and increased with disease progression, correlating strongly with progression rates and survival (p < 0.001). In contrast, NfL showed an initial elevation at diagnosis but a more limited increase over time, also correlating with survival (p = 0.001).

The implications of these findings are profound, as they not only reinforce the role of oxidative stress and neuroinflammation in ALS pathophysiology but also highlight potential biomarkers for monitoring disease progression and therapeutic efficacy. The correlation of 4-HNE and LBP with survival rates suggests that these biomarkers could serve as critical endpoints in clinical trials, particularly for evaluating new therapeutic strategies. This aligns with prior research indicating that low-dose interleukin 2 and CTLA-4 Ig can reduce these biomarkers while enhancing regulatory T cell function, demonstrating a potential avenue for therapeutic intervention.

Coya is currently advancing its investigational product, COYA 302, which combines low-dose IL-2 and CTLA-4 Ig, into a Phase 2 randomized, double-blind, placebo-controlled trial (ALSTARS). This study could significantly influence ALS treatment paradigms by providing a clearer understanding of biomarker dynamics in relation to therapeutic outcomes, potentially accelerating drug development timelines and improving patient management strategies in ALS.

Source: longevity.technology